Catalym Gmbh
Clinical trials sponsored by Catalym Gmbh, explained in plain language.
-
New antibody combo aims to boost lung cancer treatment response
Disease control Recruiting nowThis study tests whether adding the experimental drug visugromab to standard chemotherapy and immunotherapy can shrink tumors better than standard treatment alone in people with advanced non-squamous lung cancer that has not been treated before. About 107 adults with newly diagno…
Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Jul 02, 2026 08:00 UTC
-
New hope for liver cancer: Triple-Drug combo trial launches
Disease control Recruiting nowThis phase 2b trial tests whether adding visugromab and nivolumab to standard lenvatinib can help people with advanced liver cancer that has worsened after initial treatment. About 104 participants will receive either the triple combination or a placebo plus lenvatinib. The study…
Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug cocktail aims to shrink lung tumors in Late-Stage trial
Disease control Recruiting nowThis study tests a new drug called visugromab combined with nivolumab and chemotherapy (docetaxel) in people with advanced non-squamous lung cancer that has worsened after initial treatment. About 131 participants will receive different combinations to see if the new drug helps s…
Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug aims to reverse wasting in cancer patients
Symptom relief Recruiting nowThis study tests a new drug called visugromab in about 518 people with advanced cancer who are losing weight unintentionally (cachexia). The goal is to see if the drug helps them regain weight, improve appetite, and move better compared to a placebo. Participants receive the drug…
Phase: PHASE2, PHASE3 • Sponsor: CatalYm GmbH • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC